In this article, we will list the 5 Fastest Growing European Stocks to Invest In. Please visit 7 Fastest Growing European Stocks to Invest In if you would like to see the extended list and the methodology behind it.
5. Autolus Therapeutics plc (NASDAQ:AUTL)
On March 31, 2026, Mizuho lowered its price target on Autolus Therapeutics plc (NASDAQ:AUTL) to $10 from $12 previously and maintained an Outperform rating on the company shares after updating its models across its small-cap biotech coverage following the fourth quarter earnings reports.
On March 27, 2026, Autolus Therapeutics plc (NASDAQ:AUTL) reported fourth quarter EPS of (34c), compared to the (43c) consensus estimate, with revenue of $24.29 million versus $23.29 million consensus. Chief Executive Officer Christian Itin said that Autolus Therapeutics plc (NASDAQ:AUTL) had a “strong first year of launch” for AUCATZYL in the U.S., highlighting the commercial execution, product delivery, and real-world data showing clinical activity with low rates of high-grade CRS and ICANS. Chief Executive Officer Christian Itin added that the positive customer experience should support the future growth of AUCATZYL.
Autolus Therapeutics plc (NASDAQ:AUTL) develops T cell therapies for cancer and autoimmune diseases in the United Kingdom and internationally.
4. Galapagos NV (NASDAQ:GLPG)
On March 31, 2026, Galapagos NV (NASDAQ:GLPG) announced a binding agreement with Gilead Sciences (NASDAQ:GILD) related to Gilead’s planned acquisition of Ouro Medicines, a U.S.-based biotech focused on T cell engager therapies for autoimmune diseases. The deal includes access to Ouro’s clinical-stage asset gamgertamig, a BCMAxCD3 T cell engager, along with additional preclinical programs. Under the agreement, Galapagos will obtain licenses to key intellectual property, assume certain development responsibilities, and gain operational assets including facilities and personnel, effectively establishing an operating business tied to the programs. The framework also allows Galapagos to deploy at least $500M of its cash independently, including up to $150M for potential share buybacks.
Gamgertamig has received Fast Track and Orphan Drug Designation from the FDA for AIHA and ITP and is expected to enter registrational studies as early as 2027. Galapagos will fund early-stage development, while later-stage costs will be shared with Gilead, which will lead global commercialization outside certain territories. The company is also eligible for milestone payments and tiered royalties ranging from 20% to 23% on net sales.
On March 26, 2026, Galapagos NV (NASDAQ:GLPG) also announced the proposed appointment of Gino Santini as a non-executive independent director and future chair of the board, subject to shareholder approval at its April 28 annual meeting.
Galapagos NV (NASDAQ:GLPG) develops therapies focused on oncology and immunology.
3. Nyxoah SA (NASDAQ:NYXH)
On March 23, 2026, Baird analyst David Rescott lowered the price target on Nyxoah SA (NASDAQ:NYXH) to $4.62 from $5.87 and maintained a Neutral rating, citing model updates as the company’s U.S. rollout begins to gain traction but remains in its early stages.
On March 20, 2026, Stifel lowered its price target on Nyxoah SA (NASDAQ:NYXH) to $10 from $11 previously and maintained a Buy rating, noting model adjustments tied to several moving parts.
On March 19, 2026, Nyxoah SA (NASDAQ:NYXH) reported Q4 EPS of (EUR 0.59), compared to (EUR 0.46) a year ago, with revenue of EUR 5.64M versus EUR 1.26M last year. Chief Executive Officer Olivier Taelman said the quarter marked the company’s first full period of U.S. commercialization, with revenue exceeding expectations and positive feedback from surgeons and patients, alongside consistent reimbursement from major payors and Medicare.
The company expects U.S. net revenue to grow approximately 25% sequentially in both Q1 and Q2 of 2026, while international revenue is expected to follow typical seasonal patterns.
Nyxoah SA (NASDAQ:NYXH) develops neurostimulation therapies to treat obstructive sleep apnea.
2. Bicycle Therapeutics plc (NASDAQ:BCYC)
On March 18, 2026, RBC Capital lowered the price target on Bicycle Therapeutics plc (NASDAQ:BCYC) to $7 from $11 and maintained a Sector Perform rating, citing the company’s pivot away from zelenectide as a near-term setback that reduces visibility toward commercialization, though restructuring efforts could generate meaningful cost savings and support a longer-term reset.
On the same day, Oppenheimer analyst Jay Olson lowered the price target on Bicycle Therapeutics plc (NASDAQ:BCYC) to $36 from $44 and maintained an Outperform rating, noting the company’s decision to deprioritize zelenectide-pevedotin despite encouraging data, with resources being redirected toward BT5528 and next-generation programs, including its radio-conjugates portfolio.
On March 17, 2026, Bicycle Therapeutics plc (NASDAQ:BCYC) reported Q4 EPS of (29c), compared to the (95c) consensus estimate, with revenue of $47.96M versus $7.08M consensus. The company said the increase in revenue was primarily driven by recognition of remaining collaboration revenue following termination notices with partners, including Novartis and Bayer. CEO Kevin Lee said the company completed dose selection in the Duravelo-2 trial but, following regulatory feedback, decided to deprioritize zelenectide for internal development and shift focus toward other pipeline programs, alongside a broader strategic reprioritization that includes a proposed workforce reduction.
Bicycle Therapeutics plc (NASDAQ:BCYC) develops novel therapeutics for diseases with limited treatment options.
1. Marex Group plc (NASDAQ:MRX)
On March 27, 2026, TD Cowen raised the price target on Marex Group plc (NASDAQ:MRX) to $66 from $61 and maintained a Buy rating, saying updates from the company’s investor day could help support a higher valuation multiple, which the firm views as depressed.
Also on March 27, 2026, Barclays raised its price target on Marex Group plc (NASDAQ:MRX) to $55 from $50 and maintained an Overweight rating following the investor day. The firm said management struck a “confident tone” on the outlook, pointing to multiple growth drivers and potential margin upside from AI-related initiatives, while noting preliminary Q1 expectations appear ahead of Street estimates.
On March 26, 2026, Marex Group plc (NASDAQ:MRX) guided Q1 revenue to $667M-$697M versus the $588.75M consensus and sees adjusted profit before tax of $140M-$150M. The company said it expects record profitability, driven by elevated market volatility and continued growth in client balances, which averaged around $16 billion during the quarter.
Marex Group plc (NASDAQ:MRX) provides liquidity and market infrastructure services across commodity and financial markets.
While we acknowledge the potential of MRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 7 Heavily-Battered Consumer Stocks That Could Triple by 2027 and 10 Best 52-Week Low NYSE Stocks to Buy Now
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
